Our CEO Dr Rohan Hockings is pleased to present at today’s E&P Healthcare Conference. The slides can be viewed at: https://buff.ly/3Bsww9f
PYC Therapeutics (ASX: PYC)
Biotechnology
San Francisco, CA 2,294 followers
Pioneering a new generation of RNA therapeutics to change the lives of patients with severe inherited diseases
About us
PYC Therapeutics (ASX: PYC) is a clinical stage biotechnology company pioneering a new generation of RNA therapeutics for genetic diseases. It works by combining two complementary platforms: RNA-based drug design and PYC’s proprietary drug delivery technology. PYC's library of naturally derived cell penetrating peptides provide its delivery platform to overcome the major challenges of RNA therapeutics - getting into the target cell. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including two programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC’s discovery and laboratory operations are located in Australia, and the Company’s preclinical and clinical operations are based in San Fransisco California.
- Website
-
http://www.pyctx.com
External link for PYC Therapeutics (ASX: PYC)
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- San Francisco, CA
- Type
- Public Company
- Founded
- 2005
- Specialties
- RNA, Retinal disease, Rare disease, Cell-penetrating peptides, Retinitis Pigmentosa, and Neurodegenerative disease
Locations
-
Primary
Get directions
San Francisco, CA, US
-
Get directions
6 Verdun Street
Perth, Western Australia 6009, AU
Employees at PYC Therapeutics (ASX: PYC)
Updates
-
The US #FDA has granted PYC Rare Pediatric Disease (RPD) designation for its PYC-001 drug development program: https://buff.ly/4dNHGUv PYC is now eligible to receive a Priority Review Voucher upon approval of PYC-001 for vision loss associated with mutations in the OPA1 gene.
-
-
PYC will hold a webinar on Friday 30 Aug at 9am AWST/11am AEST to update investors on progress made in 2024. Shareholders are invited to attend at the McCusker Auditorium at the Harry Perkins Institute North Campus in Nedlands, WA or register online at: https://buff.ly/46WHVdi
-
-
PYC has received Human Research Ethics Committee (HREC) approval to commence clinical trials of its drug candidate in patients with Autosomal Dominant Optic Atrophy (ADOA), with first patient dosing expected to occur this quarter : https://buff.ly/3WEyEle
-
-
PYC today announces an improvement in vision in 2 additional patients with RP11 after they received a single 75 microgram dose of VP-001: https://buff.ly/46KNoDN PYC will announce further results from the ongoing multiple dose studies of VP-001 in Q4 2024.
-
-
PYC today announces several important updates for the current RP11 clinical trial: - Further improvement in visual function in a previously reported patient in the SAD study at 4 months post dosing - A second patient from the same cohort demonstrating visual function improvement at the same time point (4 months post dosing) - Both patients have reached the threshold considered to be ‘clinically significant’ on this endpoint by the FDA - The first patient dosed in the part B extension of the SAD study. This is the first patient to have received multiple doses of this drug candidate Read the full ASX Announcement here: https://lnkd.in/geUHvU2N
-
-
PYC has received Institutional Review Board approval to extend the ongoing Single Ascending Dose study in patients with RP11 into an open-label ‘Part B’ under which patients will receive multiple doses of PYC’s investigational drug candidate: https://buff.ly/3zPRD4S
-
-
PYC has now completed the first dose of its drug candidate in the first cohort of patients with RP11 in the Multiple Ascending Dose study: https://buff.ly/3zLMZ7M The study is expected to deliver both safety and efficacy data before the end of this year. #biotech #ASX
-